Finding a cure – our major research areas
Elsewhere, several research groups are testing immunotherapies (or vaccines) against the Parkinson’s hallmark protein. Immunotherapy is a method of directing our immune system to mount defences against specific pathogens or rogue proteins such as the mis-folded alpha-synuclein protein which is a common biological feature of Parkinson’s. Clinical trials of potential vaccines against alpha-synuclein are underway.
Anle138b is a small molecule that has been developed, by the German biotech company MODAG, to inhibit alpha-synuclein aggregation; and it is hoped that this treatment will slow-down or halt the progression of Parkinson’s.
Elsewhere, a biotech company is running a gene therapy trial to introduce a functional version of the GBA-1 gene into the brains of people with Parkinson’s who carry the GBA-1 mutation.